Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30063190 | 0.82 | CYP3A4 (0.32) | CA2CA1CA9HPGDCYP3A4 | |
| SCHEMBL7148753 | 0.80 | CA2 (0.41) | CA2CA1CA9RXFP1HPGD | |
| SCHEMBL6241033 | 0.80 | CA2 (0.41) | CA2CA1CA9RXFP1HPGD | |
| SCHEMBL13800900 | 0.80 | CA2 (0.41) | CA2CA1CA9RXFP1HPGD | |
| SCHEMBL13290042 | 0.80 | CA2 (0.41) | CA2CA1CA9RXFP1HPGD | |
| SCHEMBL1308779 | 0.80 | CA2 (0.41) | CA2CA1CA9RXFP1HPGD | |
| SCHEMBL6269225 | 0.80 | CA2 (0.41) | CA2CA1CA9RXFP1HPGD | |
| SCHEMBL15828255 | 0.79 | CA2 (0.42) | CA2CA1CA9RXFP1HPGD | |
| SCHEMBL7767515 | 0.78 | HPGD (0.43) | CA2CA1CA9RXFP1HPGD | |
| SCHEMBL13697309 | 0.78 | CA2 (0.36) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | CA2 4677/4885CA1 3645/4885CA9 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.